Annexon (ANNX) closed at $4.23 on November 9, 2026, up 0.7% from the previous close, on volume of 2,630,245 shares (30-day average 3,486,689).
Data as of November 9, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 5, 2026 | Seagull With Call Spread Tied to Stock | 15-Jan-272 P : 5 C : 11 C +400,000 Stock | 30,000 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 9, 2026. See the 10 largest for 30, 60 and 90 days
TipRanks (Tue, 10-Nov 8:10 AM ET)
Wells Fargo Remains a Buy on Annexon Biosciences (ANNX)
TipRanks (Tue, 10-Nov 5:56 AM ET)
Annexon Biosciences (ANNX) Receives a Buy from Bank of America Securities
TipRanks (Tue, 10-Nov 5:36 AM ET)
Annexon Biosciences GAAP EPS of -$0.25
Seeking Alpha News (Mon, 9-Nov 5:16 PM ET)
Globe Newswire (Mon, 9-Nov 4:01 PM ET)
Globe Newswire (Wed, 28-Oct 8:00 AM ET)
Annexon Spotlights 1.27 Million-Share Inducement Option Grants Priced at $3.60
Market Chameleon (Mon, 19-Oct 7:47 AM ET)
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 16-Oct 5:34 PM ET)
Globe Newswire (Thu, 24-Sep 8:00 AM ET)
Annexon to Participate in Upcoming September Investor Conferences
Globe Newswire (Wed, 2-Sep 8:00 AM ET)
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Annexon trades on the NASDAQ stock market under the symbol ANNX.
As of November 10, 2026, ANNX stock price climbed to $4.26 with 1,426,787 million shares trading.
ANNX has a beta of 0.60, meaning it tends to be less sensitive to market movements. ANNX has a correlation of 0.01 to the broad based SPY ETF.
ANNX has a market cap of $807.61 million. This is considered a Small Cap stock.
In the last 3 years, ANNX traded as high as $8.40 and as low as $1.29.
The top ETF exchange traded funds that ANNX belongs to (by Net Assets): XBI, VTI, IWM, VXF, IWO.
ANNX has outperformed the market in the last year with a price return of +47.9% while the SPY ETF gained +12.6%. However, in the short term, ANNX had mixed performance relative to the market. It has underperformed in the last 3 months, returning -21.3% vs -3.0% return in SPY. But in the last 2 weeks, ANNX shares have fared better than the market returning +15.1% compared to SPY -2.3%.
ANNX support price is $4.04 and resistance is $4.43 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANNX shares will trade within this expected range on the day.
